Join us this September for the BioHealth Capital Region Week 2024, a gathering that epitomizes the spirit of innovation in the biopharma industry. Hosted once again at US Pharmacopeia in Rockville, MD, from September 17th, 18th, and 19th, 2024, this event is made possible by the generous support of our sponsors, ensuring it remains free for all attendees. This year, we are featuring three cornerstone events: the 10th Annual BioHealth Capital Region Forum, the 9th Annual Crab Trap Competition, and the 7th Annual Investment Conference. Each event is tailored to foster unique opportunities for networking, learning, and investment, drawing together industry leaders, innovators, and investors from across the nation. We extend our heartfelt thanks to US Pharmacopeia for hosting us and to our sponsors whose contributions are vital in making these gatherings accessible to all. Click here to register and apply.

A Decade of Advancement and Achievement

This year marks the 10th anniversary of the BioHealth Capital Region Forum, and we are celebrating a decade of advancements that have positioned our region at the forefront of the biopharma industry. The Forum, spanning the first two days (September 17-18), will feature a lineup of speakers who are pioneers and thought leaders in the industry. Attendees will gain invaluable insights through keynote speeches, panel discussions, and sessions that delve into the latest innovations and trends shaping healthcare and biopharmaceuticals.

Crab Trap Competition: Where Innovation Meets Opportunity

The excitement peaks on September 18th with the 9th Annual Crab Trap Competition. This event showcases emerging companies as they pitch groundbreaking solutions to a panel of esteemed judges for a chance to win significant funding and support. It's not just a competition; it's a launchpad for the next generation of BioHealth innovations, providing startups with the visibility they need to attract investors and partners.

Connecting Innovators with Investors

The week concludes with the 7th Annual Investment Conference on September 19th, a must-attend for startups seeking investment and investors looking for the next big thing in BioHealth. This conference facilitates direct connections between up-and-coming companies and seasoned investors through curated meetings, fostering a dynamic environment for deal-making and partnership formation.

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced positive topline results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG).

Descartes-08, Cartesian’s lead product candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) directed against the B cell maturation antigen (BCMA). It is designed to be administered as an outpatient treatment without the need for lymphodepleting chemotherapy required to achieve activity with conventional CAR-T cell therapies. Descartes-08 was previously granted Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of MG.

18 projects will receive funding to support their growth and development

COLUMBIA, Md., (June 27, 2024) — TEDCO, Maryland’s economic engine for technology companies, announced the 2024 Maryland Makerspace Initiative Program (“Makerspace Program”) awardees. Funding will be awarded to 18 projects spanning across nine (9) counties and Baltimore City.

“TEDCO is committed to supporting the continued growth of innovation in Maryland. The Makerspace Program is just one tool that TEDCO has to promote this expansion,” said Terry Rauh, chief finance and operations officer at TEDCO. “And after witnessing the success and growth of last year’s awardees, we are hopeful that these awardees will continue the trend.”

BEL AIR, Md., (July 1, 2024) – Maryland Department of Commerce has awarded $500K to Baltimore-based Early Charm to develop a biomanufacturing incubator at a Harford County-owned facility near Aberdeen Proving Ground (APG). The funding from the state’s Build Our Future grant will be used to upgrade the CONVERGE Innovation Center, formerly known as the HEAT Center, located at the I-95/Aberdeen interchange.

Biomanufacturing is the use of biological processes to build new materials such as body armor made from spider silk, three times the strength of Kevlar. This technology has the potential to revolutionize manufacturing.

HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the interim results for successful completion of the second cohort of its Phase I clinical study of GalNAc-based RNAi therapeutic STP122G, targeting Factor XI as a novel form of anticoagulation agent.